|1.||Hauser, Robert A: 7 articles (05/2011 - 07/2003)|
|2.||Rascol, Olivier: 6 articles (10/2011 - 07/2003)|
|3.||Lyons, Kelly E: 6 articles (05/2010 - 07/2004)|
|4.||Asgharian, Afsaneh: 5 articles (01/2016 - 09/2008)|
|5.||Bonuccelli, Ubaldo: 5 articles (11/2014 - 12/2003)|
|6.||Stocchi, Fabrizio: 5 articles (03/2014 - 07/2003)|
|7.||Poewe, Werner: 5 articles (08/2012 - 08/2006)|
|8.||Pahwa, Rajesh: 5 articles (05/2010 - 07/2004)|
|9.||Lang, Anthony E: 5 articles (12/2007 - 01/2002)|
|10.||Reichmann, H: 5 articles (10/2005 - 09/2000)|
|1.||Parkinson Disease (Parkinson's Disease)
07/01/2000 - "In the symptomatic treatment of early Parkinson's disease ropinirole monotherapy was significantly more effective than placebo in 2 multicentre, randomised, double-blind trials of 3 to 12 months duration as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and Clinical Global Impression/Clinical Global Evaluation Scales. "
11/01/2013 - "Efficacy outcomes including Unified Parkinson's disease Rating Scale and PDQ-39 subscales of mobility were significantly improved in the ropinirole PR versus placebo group. "
10/15/2007 - "The primary endpoint-the mean reduction in the Unified Parkinson's Disease Rating Scale (UPDRS) total motor score-was significantly greater for the ropinirole group than the placebo group (-9.5 vs. -4.5, P = 0.00001). "
07/02/2013 - "The efficacy of ropinirole was assessed with the unified Parkinson's disease rating scale (UPDRS) score, "off" time according to the patient's diary and the overall evolution of clinical efficacy. "
07/02/2013 - "Ropinirole is both effective and safe in the treatment of Chinese patients with Parkinson's disease."
07/01/1997 - "Ropinirole has demonstrated efficacy in two standard preclinical models of PD and has shown a very low propensity to induce dyskinesia in these studies. "
01/01/2011 - "Patients receiving ropinirole prolonged release had a significantly greater increase in amount/percentage of awake time "on"/"on" without troublesome dyskinesia during all periods assessed (including night-time and early morning), versus placebo, and higher odds for being "on" on waking. "
09/01/2000 - "Chronic administration of ropinirole for 21 days produced a statistically significant increase in motor activity compared to the initial administration, and akinesia scores, measured through rating the quality of movements, were also improved without obvious dyskinesia. "
09/01/2008 - "In addition to controlling motor symptoms, ropinirole improved both anxiety and depressive symptoms in PD patients with motor fluctuations and/or dyskinesias. "
05/01/2006 - "In the numerous clinical trials that were carried out, it would seem clear that ropinirole can be administered for years as sole early treatment for PD and that it offers a notable reduction in the appearance of dyskinesias. "
|3.||Restless Legs Syndrome (Restless Legs)
01/01/2004 - "Symptoms of restless legs syndrome (RLS) [measured using the International Restless Legs scale and Clinical Global Impression-Global Improvement Scale scores] significantly improved with ropinirole compared with placebo in large, randomised, double-blind trials. "
09/01/2006 - "Based on the results of randomized, placebo-controlled, double-blind trials, we conclude that ropinirole is effective in reducing symptoms of restless legs syndrome in the general population. "
10/01/2006 - "Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial."
12/01/2004 - "Ropinirole is effective in the treatment of restless legs syndrome. "
10/01/2006 - "The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. "
01/01/2001 - "Withdrawal rates and adverse event frequency were similar with the two agents apart from significantly less nausea with ropinirole (odds ratio 0.50; 0.29, 0.84 95% CI; p =0.01). "
01/01/2000 - "Withdrawal rates and adverse event frequency were similar with the two agents apart from significantly less nausea with ropinirole (odds ratio 0.50; 0.29, 0. "
03/01/1998 - "Although the dopaminergic side effects were reported significantly more frequently in the ropinirole group than in the placebo group (dizziness, p = 0.0326; nausea, p = 0.001; and somnolence, p = 0.005), none necessitated study withdrawal. "
01/01/2004 - "Few patients receiving ropinirole withdrew from therapy because of adverse events, the most predominant of which were nausea and headache."
07/01/2000 - "Nausea, dizziness and somnolence were the most commonly reported adverse events and were reported at a higher incidence by patients receiving ropinirole than by those receiving placebo. "
05/01/2002 - "These results suggest that ropinirole monotherapy is effective in treating resting tremor in early PD. "
10/01/2005 - "This is the first prospective study which demonstrates beneficial effects of ropinirole on PD tremor. "
05/01/2002 - "Improvements in resting tremor were significantly better with ropinirole than placebo. "
01/01/2014 - "A rater blinded to treatment evaluated Unified Parkinson's Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects. "
05/01/2002 - "The effect of Ropinirole on tremor in early Parkinson's disease (PD) was assessed. "
|1.||Levodopa (L Dopa)
|2.||Dopamine Agonists (Dopamine Agonist)
|1.||Activities of Daily Living (ADL)
|3.||Renal Dialysis (Hemodialysis)